These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25822767)

  • 1. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.
    Peper JK; Stevanović S
    Cancer Immunol Immunother; 2015 Oct; 64(10):1295-303. PubMed ID: 25822767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
    Peper JK; Bösmüller HC; Schuster H; Gückel B; Hörzer H; Roehle K; Schäfer R; Wagner P; Rammensee HG; Stevanović S; Fend F; Staebler A
    Oncoimmunology; 2016 May; 5(5):e1065369. PubMed ID: 27467910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
    Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
    Noguchi M; Sasada T; Itoh K
    Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
    Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
    Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
    Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
    Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant HER2/neu peptide cancer vaccines in breast cancer.
    Clifton GT; Mittendorf EA; Peoples GE
    Immunotherapy; 2015; 7(11):1159-68. PubMed ID: 26567563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
    Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
    Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
    Mühlenbruch L; Abou-Kors T; Dubbelaar ML; Bichmann L; Kohlbacher O; Bens M; Thomas J; Ezić J; Kraus JM; Kestler HA; von Witzleben A; Mytilineos J; Fürst D; Engelhardt D; Doescher J; Greve J; Schuler PJ; Theodoraki MN; Brunner C; Hoffmann TK; Rammensee HG; Walz JS; Laban S
    Br J Cancer; 2023 May; 128(9):1777-1787. PubMed ID: 36823366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human leukocyte antigen-presented ligandome of B lymphocytes.
    Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
    Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
    Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.